Enzyme News and Research

RSS

Study shows molecular mechanism of SARS-CoV-2 Mpro

The Computational Biochemistry Group's research has been selected as one of the most outstanding studies of 2020 by the journal Chemical Science.

23 Jul 2020

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

In a new bioRxiv study, authors identified a isoform of ACE2 (designated as deltaACE2 or dACE2) receptor, shown to be induced in various human cell types.

23 Jul 2020

Mysterious enzyme inhibits inflammation in blood vessels, LJI study shows

Scrape your knee, and you'll see some red puffiness appear around the injury. This is inflammation, and it is driven by the immune system.

23 Jul 2020

Study finds viable drug target for triple negative breast cancer

One member of a larger family of oxygen sensing enzymes could offer a viable target for triple negative breast cancer (TNBC), UTSW researchers report in a new study.

23 Jul 2020

Malaria drug does not prevent infection of human lung cells with novel coronavirus

More than 600,000 people worldwide have fallen victim to the lung disease COVID-19 so far, which is caused by the SARS coronavirus-2 (SARS-CoV-2).

22 Jul 2020

Erectile dysfunction drugs lower the accumulation of toxic proteins in zebrafish models

The aberrant buildup of misfolded proteins is a hallmark of a host of disorders, including neurodegenerative diseases such as Alzheimer's and Parkinson's.

22 Jul 2020

Study shows chloroquine does not prevent SARS-CoV-2

More than 600,000 people worldwide have fallen victim to the lung disease COVID-19 so far, which is caused by the SARS coronavirus-2 (SARS-CoV-2).

22 Jul 2020

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

As COVID-19 continues to spread over the world scientists continue to seek the reasons for the difference in disease severity from person to person.

22 Jul 2020

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020

High-quality lab procedures crucial to discovery of effective drugs

In their quest to find new drugs to treat deadly diseases, scientists study millions of molecules at high speed at the same time. Often it is enzymes that are investigated as targets in these 'high-throughput' screenings.

21 Jul 2020

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Now, a new study published on the preprint server bioRxiv in July 2020 presents an engineered transgenic mouse that reproduces the functional and clinical characteristics of severe human SARS-CoV-2 infection.

21 Jul 2020

Study may lead to new diagnostic and treatment strategies for fighting bone cancer

Osteosarcoma (OS) is the most common form of aggressive bone cancer. A MedUni Vienna study, led by geneticist Erwin Wagner, has uncovered new insights into the disease mechanisms of OS, paving the way for potential new diagnostic and treatment strategies for fighting the bone disease

21 Jul 2020

New assay improves detection of SARS-CoV-2 antibodies

Researchers at the University of California Santa Cruz have developed a new assay for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that they say provides significant advantages over the techniques currently used.

20 Jul 2020

Novel blood test for heart failure could lead to new diagnostics for COVID-19 patients

A new blood test that reliably predicts outcomes for heart failure patients could lead to new diagnostics and treatments for COVID-19 patients as well, according to newly published research from cardiologists at the University of Alberta.

20 Jul 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Fluidic Sciences and Sphere Bio 20 Jul 2020

Study shows a promising, new approach to treating Alzheimer's disease

With over 1.2 million people affected in Germany alone and over 50 million people worldwide, Alzheimer's disease, also referred to simply as Alzheimer's, is one of the greatest medical and social challenges of our time.

17 Jul 2020

More COVID-19 cases where blood type A is common

Now, a new study by researchers at the University of Ulm, Germany, which is published on the preprint server medRxiv in July 2020, focuses on how blood group distribution is related to the mapped dynamics of the epidemic as shown by its geographical distribution.

17 Jul 2020

Newly identified enzyme provides a new tool in CRISPR genome editing toolbox

A recently discovered hypercompact CRISPR enzyme found only in huge bacteriophages, and known as CRISPR-CasΦ, is functional, a new study by Patrick Pausch, Jennifer Doudna and colleagues reports, and it provides a powerful new tool in the CRISPR genome editing toolbox, including because it can target a wider range of genetic sequences compared to Cas9 and Cas12.

17 Jul 2020

Game-Changer: A SARS-CoV-2 serological test for 50-cents per sample!

A recent study published in the preprint server medRxiv in July 2020 shows that this is indeed possible. The development of this inexpensive but reliable and sensitive test could change the face of preventive measures for COVID-19 in low-resource settings.

17 Jul 2020

Common antioxidant enzyme catalase as COVID-19 treatment

A new paper by researchers from the USA and China and published on the preprint server bioRxiv in July 2020 discusses a new drug based on the catalase enzyme, which could play a vital part in reducing the inflammation associated with progressive and severe COVID-19 disease.

17 Jul 2020

Enzyme News and Research

Study shows molecular mechanism of SARS-CoV-2 Mpro

Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor

Mysterious enzyme inhibits inflammation in blood vessels, LJI study shows

Study finds viable drug target for triple negative breast cancer

Malaria drug does not prevent infection of human lung cells with novel coronavirus

Erectile dysfunction drugs lower the accumulation of toxic proteins in zebrafish models

Study shows chloroquine does not prevent SARS-CoV-2

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

High-quality lab procedures crucial to discovery of effective drugs

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Study may lead to new diagnostic and treatment strategies for fighting bone cancer

New assay improves detection of SARS-CoV-2 antibodies

Novel blood test for heart failure could lead to new diagnostics for COVID-19 patients

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Study shows a promising, new approach to treating Alzheimer's disease

More COVID-19 cases where blood type A is common

Newly identified enzyme provides a new tool in CRISPR genome editing toolbox

Game-Changer: A SARS-CoV-2 serological test for 50-cents per sample!

Common antioxidant enzyme catalase as COVID-19 treatment

Biochemical Assays for Efficient Hit Prioritization After Screening eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo